Trial Profile
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis: A Phase II Randomized Placebo Controlled Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 31 Mar 2020 Status changed from recruiting to completed.
- 19 Aug 2019 Planned End Date changed from 30 Jun 2020 to 30 Dec 2019.
- 19 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.